Prevention of graft vs. host disease with alemtuzumab ‘in the bag’ decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome

References

• Cavo M, Benni M, Ronconi S, et al. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica 2002; 87: 934–42
   PubMed Web of Science ®Google Scholar
• Cornwell GG, Pajak TF, Kochwa S, et al. Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma: Cancer and Leukemia Group B experience. Cancer 1982; 50: 1669–75
   Google Scholar
• Oken MM. Multiple myeloma. Med Clin North Am 1984; 68: 757–87
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Rowley SD, Demire T, et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447–56
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B, Hagman A, Ljungman P , et al. Autologous stem cell transplantation in multiple myeloma: an update of the EBMT registry. In: VIII International Myeloma Workshop. Banff: Blackwell, European Journal of Haematology, Volume 67, Number 3, September 2001, pp. 199–202.
   Google Scholar
• Blade J, Esteve J, Rives S, et al. High-dose therapy autotransplantation/intensification vs. continued standard chemotherapy in multiple myeloma in first remission: results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845–9
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. New Engl J Med 1996; 335: 91–7
   PubMed Web of Science ®Google Scholar
• Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study, Nordic Myeloma Study Group. Blood 2000; 95: 7–11
   PubMed Web of Science ®Google Scholar
• Corradini P, Voena C, Astolfi M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596–602
   PubMed Web of Science ®Google Scholar
• Stewart K, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–9
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–8
   PubMed Web of Science ®Google Scholar
• Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–18
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–11
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031–7
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Demirer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996; 18: 527–31
   PubMed Web of Science ®Google Scholar
• Novitzky N, Thomas V, Hale G, et al. Campath-1 Abs ‘in the bag’ for hematological malignancies: The Cape Town experience. Cytotherapy 2004; 6: 172–81
   PubMed Web of Science ®Google Scholar
• Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69–76
   PubMed Web of Science ®Google Scholar
• Novitzky N, Thomas V, Hale G, et al. Myeloablative conditioning is well tolerated by older patients receiving T-cell depleted grafts. Bone Marrow Transplant 2005; 36: 675–82
   Google Scholar
• Hale G, Xia M-Q, Tighe HP, et al. The CAMPATH-1 antigen (Cdw 52). Tissue Antig 1990; 35: 118–27
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–20
   PubMed Web of Science ®Google Scholar
• Hickman RO, Buckner CD, Clift RA, et al. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet 1979; 148: 871–5
   PubMedGoogle Scholar
• Novitzky N, Rouskova A. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation. Cytotherapy 2001; 3: 165–73
   PubMed Web of Science ®Google Scholar
• Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423–8
   PubMed Web of Science ®Google Scholar
• Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213–26
   PubMedGoogle Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft vs host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420–7
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–4
   PubMed Web of Science ®Google Scholar
• Richardson P, Schlossman R, Hideshima T, et al. A phase I trial of oral CC-5013, an immunomodulatory thalidomide derivative, in patients with relapsed and refractory multiple myeloma. Blood 2001; 98: 775a
   Google Scholar
• Bjorkstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–18
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Segeren CM, Verdonck LF, et al. For the Dutch-Belgian Hemato-Oncology Cooperative Group. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003; 21: 1728–33
   PubMed Web of Science ®Google Scholar
• Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9: 257–65
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532–9
   PubMed Web of Science ®Google Scholar
• Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404–6
   PubMed Web of Science ®Google Scholar